PharmaShots | Incisive News in 3 Shots

Subscribe Now

Non-Metastatic Castration-Resistant Prostate Cancer

Bayer's Nubeqa (darolutamide) Receives the EC's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Bayer's Nubeqa (darolutamide) Receives the EC's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

March 31, 2020

Astellas and Pfizer Report Results of Xtandi (enzalutamide) in P-III PROSPER Study for Non-Metastatic Castration-Resistant Prostate Cancer

Astellas and Pfizer Report Results of Xtandi (enzalutamide) in P-III PROSPER Study for Non-Metastatic Castration-Resistant Prostat...

February 12, 2020

Bayer Reports Results of Darolutamide in P-III ARAMIS trial for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Bayer Reports Results of Darolutamide in P-III ARAMIS trial for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

February 15, 2019

Janssen's Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)

Janssen's Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)

February 14, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us